Clinic of Cystic Fibrosis, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Basic Med Sci. 2013 Aug;16(8):917-21.
OBJECTIVE(S): More than 1500 registered mutations in cystic fibrosis transmembrane regulator (CFTR) gene are responsible for dysfunction of an ion channel protein and a wide spectrum of clinical manifestations in patients with cystic fibrosis (CF). This study was performed to investigate the frequency of a number of well-known CFTR mutations in North Eastern Iranian CF patients.
A total number of 56 documented CF patients participated in this study. Peripheral blood was obtained and DNA extraction was done by the use of routin methods. Three steps were taken for determining the target mutations: ARMS-PCR was performed for common CFTR mutations based on previous reports in Iran and neighboring countries. PCR-RFLP was done for detection of R344W and R347P, and PCR-Sequencing was performed for exon 11 in patients with unidentified mutation throughout previous steps. Samples which remained still unknown for a CFTR mutation were sequenced for exon 12.
Among 112 alleles, 24 mutated alleles (21.42%) were detected: ΔF508 (10.71%), 1677delTA (3.57%), S466X (3.57%), N1303K (0.89%), G542X (0.89%), R344W (0.89%), L467F (0.89%). Eight out of 56 individuals analyzed, were confirmed as homozygous and eight samples showed heterozygous status. No mutations were detected in exon 12 of sequenced samples.
Current findings suggest a selected package of CFTR mutations for prenatal, neonatal and carrier screening along with diagnosis and genetic counseling programs in CF patients of Khorasan.
囊性纤维化跨膜转导调节因子 (CFTR) 基因中超过 1500 个注册突变导致离子通道蛋白功能障碍,并使囊性纤维化 (CF) 患者表现出广泛的临床症状。本研究旨在调查东北伊朗 CF 患者中一些已知 CFTR 突变的频率。
共有 56 名确诊 CF 患者参与了这项研究。采集外周血,采用常规方法提取 DNA。确定目标突变的步骤如下:根据伊朗和邻国的先前报告,采用 ARMS-PCR 检测常见 CFTR 突变;采用 PCR-RFLP 检测 R344W 和 R347P,采用 PCR-测序检测前两步中未鉴定突变的患者外显子 11;对仍未鉴定 CFTR 突变的样本进行外显子 12 测序。
在 112 个等位基因中,检测到 24 个突变等位基因(21.42%):ΔF508(10.71%)、1677delTA(3.57%)、S466X(3.57%)、N1303K(0.89%)、G542X(0.89%)、R344W(0.89%)、L467F(0.89%)。在分析的 56 个人中,有 8 个人被确认为纯合子,8 个样本显示为杂合子。在测序样本中未检测到外显子 12 的突变。
本研究结果提示,在 CF 患者的产前、新生儿和携带者筛查、诊断和遗传咨询计划中,应选择一套特定的 CFTR 突变检测方案。